Management of endometrial cancer in Latin America: raising the standard of care and optimizing outcomes.

33 In addition, interim analysis of overall survival indicated a positive trend for atezolizumab in the MMRd population. 33 38 The safety profile was consistent with expected toxicities. 33 38 In the phase III DUO-E trial, which also included patients with advanced or recurrent endometrial cancer, the combination of carboplatin plus paclitaxel with durvalumab (a PD-L1 inhibito

also in 11,005 other papers